The effects of ovarian function suppression (OFS) on survival and patient–reported outcomes were evaluated in a phase III trial in which premenopausal women were randomly assigned to tamoxifen with or without OFS.

When added to tamoxifen, OFS results in more menopausal symptoms and sexual dysfunction, which contributes to inferior self–reported health–related quality of life. Because of early closure, this study is underpowered for drawing conclusions about the impact on survival when adding OFS to tamoxifen.

READ FULL ARTICLE Curated publisher From Mdlinx